Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The price of abandoning diagnostic testing for cell‐free fetal DNA screening

8 Feb 2018

Abstract excerpt

Over 50 years, prenatal diagnosis procedures and screening have become safer and diagnostic laboratory capabilities have dramatically expanded,1-5 Recently, cell-free fetal DNA (cffDNA) utilization has gained considerable market share. While officially, companies state that cffDNA is screening and not diagnostic, much of the sales “hype” and patient and physician understanding is that cffDNA is a replacement—not...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Fetal and Pediatric Neurological Disorders
Share to Genomic variations and chromosomal abnormalities
Share to Prenatal Screening and Diagnostics

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29417598
DOI: 10.1002/pd.5226

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

The price of abandoning diagnostic testing for cell‐free fetal DNA screeningPMID 29417598Read ↗

The price of performance: a cost and performance analysis of the implementation of cell‐free fetal DNA testing for Down syndrome in Ontario, CanadaSemantic proximity Read ↗

An Economic Analysis of Cell-Free DNA Non-Invasive Prenatal Testing in the US General Pregnancy PopulationSemantic proximity Read ↗

A cost‐effectiveness analysis of cell free DNA as a replacement for serum screening for Down syndromeSemantic proximity Read ↗

Cell‐free fetal <scp>DNA</scp> screening in the USA: a cost analysis of screening strategiesSemantic proximity Read ↗

Rapid testing versus karyotyping in Down's syndrome screening: cost-effectiveness and detection of clinically significant chromosome abnormalitiesSemantic proximity Read ↗

Costs and Clinical Outcomes of Noninvasive Fetal RhD Typing for Targeted ProphylaxisSemantic proximity Read ↗

Incorporating DNA Sequencing into Current Prenatal Screening Practice for Down's SyndromeSemantic proximity Read ↗

Cost-effectiveness of noninvasive fetal RhD blood group genotyping in nonalloimmunized and alloimmunized pregnancies.Semantic proximity Read ↗

Noninvasive Fetal RhD Blood Group Genotyping: A Health Technology Assessment.Semantic proximity Read ↗

New estimates of down syndrome risks at chorionic villus sampling, amniocentesis, and livebirth in women of advanced maternal age from a uniquely defined populationSemantic proximity Read ↗

Changes in the Utilization of Prenatal DiagnosisSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.